The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
Abstract
BACKGROUND: Recurrent oral and genital ulcers are the most frequent problem in the management of the Behçet syndrome. Uncontrolled experience suggests that thalidomide may help prevent recurrences of these ulcers. OBJECTIVE: To determine the efficacy of two thalidomide dosages in the treatment of mucocutaneous lesions of the Behçet syndrome. DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: Specialist outpatient clinic for the Behçet syndrome in Turkey. PATIENTS: 96 male patients with the Behçet syndrome who primarily had mucocutaneous lesions without major organ involvement. INTERVENTION: Thalidomide, 100 mg/d or 300 mg/d, or placebo for 24 weeks. MEASUREMENTS: Sustained absence of any oral and genital ulceration during treatment (complete response) and changes in the number of mucocutaneous lesions. An additional evaluation was done 4 weeks after treatment ended. RESULTS: A complete response occurred in 2 of the 32 patients (6% [95% CI, 0.8% to 20.8%]) receiving thalidomide, 100 mg/d; in 5 of the 31 patients (16% [CI, 5.5% to 33.7%]) receiving thalidomide, 300 mg/d; and in none of the 32 patients (0% [CI, 0% to 10.9%]) receiving placebo (P = 0.031). The suppressive effect of thalidomide with either dosage was evident at 4 weeks for oral ulcers (P < 0.001) and at 8 weeks for genital ulcers (P < 0.001) and follicular lesions (P = 0.008). This effect persisted during treatment but diminished rapidly after treatment was discontinued. Both thalidomide dosages led to significant increases in the number of erythema nodosum lesions during the first 8 weeks of treatment (P = 0.03). Polyneuropathy developed in 4 patients (1 in the 100-mg/d group and 3 in the 300-mg/d group); in 3 of these patients, the condition was diagnosed after the trial had ended. CONCLUSIONS: Thalidomide is effective for treating the oral and genital ulcers and follicular lesions of the Behçet syndrome. A dosage of 100 mg/d is as effective as a dosage of 300 mg/day.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Criteria for diagnosis of Behçet's disease
Weichsler, B., Davatchi, F., Lehner, T., O’Duffy, J. D., Rigby, A. S., & Gregory, J. K. (1990) · The Lancet · Cited by 3,082
A Controlled Trial of Azathioprine in Behçet's Syndrome
Yazici, H., Pazarli, H., Barnes, C. G., Tüzün, Y., Özyazgan, Y., Silman, A., Serdaroğlu, S., Oğuz, V., Yurdakul, S., Lovatt, G. E., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002013220501 · Cited by 647
Self-citationJacobson, J. M., Greenspan, J. S., Spritzler, J., Ketter, N., Fahey, J. L., Jackson, J. B., Fox, L., Chernoff, M., Wu, A. W., MacPhail, L. A., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705223362103 · Cited by 420
Yazici, H., Tüzün, Y., Pazarli, H., Yurdakul, S., Ozyazgan, Y., Ozdoğan, H., Serdaroğlu, S., Ersanli, M., Ulkü, B. Y., & Müftüoğlu, A. U. (1984) · Annals of the Rheumatic Diseases · doi:10.1136/ard.43.6.783 · Cited by 411
Self-citationRediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses
Tseng, S., Pak, G., Washenik, K., Keltz Pomeranz, M., & Shupack, J. L. (1996) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(96)90122-x · Cited by 367
Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study.
Fullerton, P. M., & O'Sullivan, D. J. (1968) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.31.6.543 · Cited by 203
Gastrointestinal involvement in Behçet's syndrome: a controlled study.
Yurdakul, S., Tüzüner, N., Yurdakul, I., Hamuryudan, V, & Yazici, H. (1996) · Annals of the Rheumatic Diseases · doi:10.1136/ard.55.3.208 · Cited by 175
Self-citationThalidomide-induced peripheral neuropathy
Hess, C. W., Hunziker, T., K�pfer, A., & Ludin, H. P. (1986) · Journal of Neurology · doi:10.1007/bf00313852 · Cited by 72
Cited by
Sakane, T., Takeno, M., Suzuki, N., & Inaba, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910213411707 · Cited by 1,594
Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients
Akman-Demir, G., Serdaroglu, P., & Tasçi, B. (1999) · Brain · doi:10.1093/brain/122.11.2171 · Cited by 793
Kural-Seyahi, E., Fresko, I., Seyahi, N., Ozyazgan, Y., Mat, C., Hamuryudan, V., Yurdakul, S., & Yazici, H. (2003) · Medicine · doi:10.1097/00005792-200301000-00006 · Cited by 768
Self-citationEULAR recommendations for the management of Behçet disease
Hatemi, G., Silman, A., Bang, D., Bodaghi, B., Chamberlain, A. M., Gul, A., Houman, M. H., Kötter, I., Olivieri, I., Salvarani, C., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.080432 · Cited by 718
Self-citationCorral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L.-M., Ocampo, C. J., Patterson, R. T., Stirling, D. I., & Kaplan, G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.380 · Cited by 656
Metadata
- Authors
- Hamuryudan, V., Mat, C., Saip, S., Ozyazgan, Y., Siva, A., Yurdakul, S., Zwingenberger, K., & Yazici, H.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1998-03-15
- Volume
- 128
- Issue
- 6
- Pages
- 443-450
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2104613102
- Cited by
- 456
- References
- 8
- FWCI
- 29.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.7326/0003-4819-128-6-199803150-00004
- The paper
- Hamuryudan, V., Mat, C., Saip, S., Ozyazgan, Y., Siva, A., Yurdakul, S., Zwingenberger, K., & Yazici, H. (1998). Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-128-6-199803150-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.